Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer.

Ulmann G, Jouinot A, Tlemsani C, Curis E, Kousignian I, Neveux N, Durand JP, Goldwasser F, Cynober L, De Bandt JP.

Ann Nutr Metab. 2019;75(4):223-230. doi: 10.1159/000504874. Epub 2019 Dec 19.

PMID:
31865308
2.

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.

Huillard O, Jouinot A, Tlemsani C, Brose MS, Arrondeau J, Meinhardt G, Fellous M, De Sanctis Y, Schlumberger M, Goldwasser F.

Thyroid. 2019 Dec;29(12):1820-1827. doi: 10.1089/thy.2018.0784.

3.

The impact of body composition parameters on severe toxicity of nivolumab.

Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F.

Eur J Cancer. 2020 Jan;124:170-177. doi: 10.1016/j.ejca.2019.11.003. Epub 2019 Nov 30.

PMID:
31794927
4.

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature.

Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F, Oudard S, Weiss L.

J Immunother Cancer. 2019 Dec 2;7(1):335. doi: 10.1186/s40425-019-0822-7.

5.

Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B.

Cancers (Basel). 2019 Nov 13;11(11). pii: E1784. doi: 10.3390/cancers11111784.

6.

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K.

J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3.

7.

Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.

Joulia ML, Carton E, Jouinot A, Allard M, Huillard O, Khoudour N, Peyromaure M, Zerbib M, Schoemann AT, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

Clin Genitourin Cancer. 2019 Jun 13. pii: S1558-7673(19)30158-2. doi: 10.1016/j.clgc.2019.05.020. [Epub ahead of print]

PMID:
31630979
8.

Pericardial effusion under nivolumab: case-reports and review of the literature.

Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F, Oudard S, Weiss L.

J Immunother Cancer. 2019 Oct 18;7(1):266. doi: 10.1186/s40425-019-0760-4. Erratum in: J Immunother Cancer. 2019 Dec 2;7(1):335.

9.

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

Jouinot A, Ulmann G, Vazeille C, Durand JP, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Fournel L, Alifano M, Wislez M, Chapron J, Le Bris C, Mansuet-Lupo A, Damotte D, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F.

Clin Nutr. 2019 Aug 10. pii: S0261-5614(19)30315-2. doi: 10.1016/j.clnu.2019.08.003. [Epub ahead of print]

PMID:
31443979
10.

Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers.

Bouaoud J, Beinse G, Epaillard N, Amor-Sehlil M, Bidault F, Brocheriou I, Hervé G, Spano JP, Janot F, Boudou-Rouquette P, Benassarou M, Schouman T, Goudot P, Malouf G, Goldwasser F, Bertolus C.

Oral Oncol. 2019 Aug;95:79-86. doi: 10.1016/j.oraloncology.2019.06.011. Epub 2019 Jun 11.

PMID:
31345398
11.

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Noé G, Bellesoeur A, Golmard L, Thomas-Schoemann A, Boudou-Rouquette P, Tiako Meyo M, Puszkiel A, Arrondeau J, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Cancers (Basel). 2019 May 31;11(6). pii: E762. doi: 10.3390/cancers11060762.

12.

[Multidisciplinary and systematic preoperatory-assessment in geriatric urologic oncology surgery: Feasibility and results].

Prin-Touvron L, Huillard O, Xylinas E, Orvoen G, Boudou-Rouquette P, Barry Delongchamps N, Zerbib M, Peyromaure M, Alexandre J, Goldwasser F.

Prog Urol. 2019 May - Jun;29(6):318-325. doi: 10.1016/j.purol.2019.04.008. Epub 2019 May 29. French.

PMID:
31153857
13.

Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation.

Colombet I, Bouleuc C, Piolot A, Vilfaillot A, Jaulmes H, Voisin-Saltiel S, Goldwasser F, Vinant P; EFIQUAVIE study group.

BMC Palliat Care. 2019 Apr 5;18(1):35. doi: 10.1186/s12904-019-0419-4.

14.

The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.

Beinse G, Just PA, Rance B, Izac B, Letourneur F, Saidu NEB, Chouzenoux S, Nicco C, Goldwasser F, Pasmant E, Batteux F, Borghese B, Alexandre J, Leroy K.

PLoS One. 2019 Mar 25;14(3):e0214416. doi: 10.1371/journal.pone.0214416. eCollection 2019.

15.

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.

Cohen R, Preta LH, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

Br J Clin Pharmacol. 2019 Jun;85(6):1227-1238. doi: 10.1111/bcp.13849. Epub 2019 Jan 30.

PMID:
30701582
16.

RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.

Huillard O, Le Strat Y, Dubertret C, Goldwasser F, Mallet J.

J Natl Cancer Inst. 2019 Mar 1;111(3):335-336. doi: 10.1093/jnci/djz003. No abstract available.

PMID:
30629204
17.

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study.

Jouinot A, Royer B, Chatelut E, Moeung S, Assié G, Thomas-Schoemann A, Bertherat J, Goldwasser F, Blanchet B.

Endocr Connect. 2018 Dec 1;7(12):1409-1414. doi: 10.1530/EC-18-0428.

18.

Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?

Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, Neuzillet C, Goldwasser F.

Pharmacol Ther. 2019 Apr;196:135-159. doi: 10.1016/j.pharmthera.2018.12.003. Epub 2018 Dec 4. Review.

PMID:
30521882
19.

[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].

Gaultier De Saint Basile H, Poisson C, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Tartour E, De Guillebon E.

Bull Cancer. 2018 Dec;105(12):1202-1208. doi: 10.1016/j.bulcan.2018.10.004. Epub 2018 Nov 22. French.

PMID:
30471959
20.

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma.

Saade A, Carton E, Mansuet-Lupo A, Jouffroy R, Damotte D, Yera H, Revel MP, Goldwasser F.

Emerg Infect Dis. 2018 Dec;24(12):2375-2378. doi: 10.3201/eid2412.180355.

21.

Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey.

Mallet J, Huillard O, Goldwasser F, Dubertret C, Le Strat Y.

Eur J Cancer. 2018 Dec;105:10-18. doi: 10.1016/j.ejca.2018.09.038. Epub 2018 Oct 30.

PMID:
30388660
22.

Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.

Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P.

J Med Genet. 2020 Feb;57(2):104-108. doi: 10.1136/jmedgenet-2018-105594. Epub 2018 Oct 23.

PMID:
30352869
23.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
24.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Review. French.

PMID:
30337201
25.

[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].

Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A.

Bull Cancer. 2018 Nov;105(11):1102-1109. doi: 10.1016/j.bulcan.2018.08.005. Epub 2018 Oct 8. French.

PMID:
30309623
26.

Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key.

Tiako Meyo M, Alexandre J, Goldwasser F, Blanchet B.

J Clin Oncol. 2018 Oct 20;36(30):3061-3062. doi: 10.1200/JCO.2018.79.3174. Epub 2018 Sep 6. No abstract available.

PMID:
30188788
27.

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.

Blanchet B, Carton E, Alyamani M, Golmard L, Huillard O, Thomas-Scheomann A, Vidal M, Goldwasser F, Sharifi N, Alexandre J.

Pharmacol Res. 2018 Oct;136:56-61. doi: 10.1016/j.phrs.2018.08.016. Epub 2018 Aug 22.

PMID:
30142421
28.

Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.

Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J, Goldwasser F, Blanchet B.

Crit Rev Oncol Hematol. 2018 Sep;129:102-112. doi: 10.1016/j.critrevonc.2018.06.015. Epub 2018 Jul 9. Review.

PMID:
30097228
29.

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.

Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Review.

PMID:
30094711
30.

[Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results].

Chabanol H, Huillard O, Prin L, Villeminey C, Rondeau A, Boudou-Rouquette P, Astorg F, Musenghesi B, Du Mortier C, Alexandre J, Goldwasser F.

Bull Cancer. 2018 Dec;105(12):1173-1182. doi: 10.1016/j.bulcan.2018.06.005. Epub 2018 Aug 2. French.

PMID:
30078546
31.

BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine.

Tlemsani C, Pasmant E, Boudou-Rouquette P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F.

Am J Med Sci. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1. Review.

PMID:
30041945
32.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, Thomas-Schoemann A, Arrondeau J, Giraud F, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2018 Sep 5;158:174-183. doi: 10.1016/j.jpba.2018.05.052. Epub 2018 Jun 1.

PMID:
29883880
33.

Nivolumab combined with ruxolitinib: antagonism or synergy?

Debureaux PE, Arrondeau J, Bouscary D, Goldwasser F.

Ann Oncol. 2018 May 1;29(5):1334-1335. doi: 10.1093/annonc/mdy077. No abstract available.

PMID:
29788168
34.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

35.

Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.

Goldwasser F, Vinant P, Aubry R, Rochigneux P, Beaussant Y, Huillard O, Morin L.

Cancer. 2018 Jul 15;124(14):3044-3051. doi: 10.1002/cncr.31536. Epub 2018 May 9.

36.

[Renal toxicity of high-dose methotrexate].

Garcia H, Leblond V, Goldwasser F, Bouscary D, Raffoux E, Boissel N, Broutin S, Joly D.

Nephrol Ther. 2018 Apr;14 Suppl 1:S103-S113. doi: 10.1016/j.nephro.2018.02.015. French.

PMID:
29606256
37.

[Multidisciplinary oncopalliative meeting: Aims and pratical recommendations].

Goldwasser F, Nisenbaum N, Vinant P, Balladur E, Dauchy S, Farota-Romejko I, Colombet I, Alby ML, Giroux J, Larrouy A, Destaintot E, Garcon L, Legrand D, Marin I; groupe soins palliatifs en cancérologie de l’ARS d’Île-de-France.

Bull Cancer. 2018 May;105(5):458-464. doi: 10.1016/j.bulcan.2018.01.017. Epub 2018 Mar 19. French.

38.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
39.

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.

Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J.

Oncotarget. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6.

40.

Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 Study.

Gyan E, Raynard B, Durand JP, Lacau Saint Guily J, Gouy S, Movschin ML, Khemissa F, Flori N, Oziel-Taieb S, Bannier Braticevic C, Zeanandin G, Hebert C, Savinelli F, Goldwasser F, Hébuterne X; NutriCancer2012 Investigator Group.

JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):255-260. doi: 10.1177/0148607116688881. Epub 2017 Dec 11.

PMID:
29505137
41.

Resting energy metabolism and anticancer treatments.

Jouinot A, Vazeille C, Goldwasser F.

Curr Opin Clin Nutr Metab Care. 2018 May;21(3):145-151. doi: 10.1097/MCO.0000000000000457. Review.

PMID:
29369114
42.

Restoring Radioiodine Uptake in BRAF V600E-Mutated Papillary Thyroid Cancer.

Huillard O, Tenenbaum F, Clerc J, Goldwasser F, Groussin L.

J Endocr Soc. 2017 Feb 21;1(4):285-287. doi: 10.1210/js.2016-1114. eCollection 2017 Apr 1.

43.

[Crossed perceptions about malnutrition in patients and their doctors in oncology].

Raynard B, Hébuterne X, Goldwasser F, Ait Hssain A, Dubray Longeras P, Barthélémy P, Rosso E, Phoutthasang V, Bories C, Digue L, Laharie D, Desport JC, Falkowski S, Lacau Saint Guily J, Gyan E.

Bull Cancer. 2017 Nov;104(11):921-928. doi: 10.1016/j.bulcan.2017.09.014. Epub 2017 Nov 8. French.

PMID:
29128080
44.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
45.

Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.

Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F.

Fundam Clin Pharmacol. 2018 Feb;32(1):98-107. doi: 10.1111/fcp.12327. Epub 2017 Nov 10.

PMID:
29055166
46.

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.

Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O.

Drug Des Devel Ther. 2017 Sep 21;11:2801-2811. doi: 10.2147/DDDT.S109640. eCollection 2017. Review.

47.

Individualized Pazopanib Dosing-Letter.

Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B.

Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. No abstract available.

48.

NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer.

Lacau St Guily J, Bouvard É, Raynard B, Goldwasser F, Maget B, Prevost A, Seguy D, Romano O, Narciso B, Couet C, Balon JM, Vansteene D, Salas S, Grandval P, Gyan E, Hebuterne X.

J Geriatr Oncol. 2018 Jan;9(1):74-80. doi: 10.1016/j.jgo.2017.08.003. Epub 2017 Sep 6.

PMID:
28888553
49.

Reply to N Dominguez and T Canada.

Vazeille C, Jouinot A, Durand JP, Cynober L, Goldwasser F.

Am J Clin Nutr. 2017 Sep;106(3):958-959. doi: 10.3945/ajcn.117.162107. No abstract available.

PMID:
28864589
50.

[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs].

de Percin S, Fidelle M, Carton E, Goldwasser F.

Bull Cancer. 2017 Sep;104(9):807-811. doi: 10.1016/j.bulcan.2017.06.005. Epub 2017 Aug 4. French. No abstract available.

PMID:
28784244

Supplemental Content

Loading ...
Support Center